Vorinostat, a Histone Deacetylase Inhibitor, in Combination with Thoracic Radiotherapy in Advanced Non-small Cell Lung Cancer: A Dose Escalation Study

被引：2
|
作者：
Decker, R. H. [1 ]
Gettinger, S. N. [1 ]
Glazer, P. M. [1 ]
Wilson, L. D. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.1074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S574 / S575
页数：2
相关论文
共 50 条
  • [1] VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR, IN COMBINATION WITH THORACIC RADIOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: A DOSE ESCALATION STUDY
    Decker, Roy H.
    Gettinger, Scott N.
    Glazer, Peter M.
    Wilson, Lynn D.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1550 - S1551
  • [2] Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.
    Reid, T
    Weeks, A
    Vakil, M
    Cosgriff, T
    Harper, T
    Valone, F
    Magnuson, D
    Bhatnagar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 685S - 685S
  • [3] A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer
    Decker, R. H.
    Gettinger, S. N.
    Wilson, L. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase I Dose Escalation Study of Thoracic Radiotherapy in Combination with Gefitinib in Patients with IIIB/IV Non-small Cell Lung Cancer
    Chen, J.
    Fan, M.
    Jiang, G.
    Fu, X.
    Xie, L.
    Xu, X.
    Zhang, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S110 - S111
  • [6] The histone deacetylase inhibitor, vorinostat, increases carboplatin and paclitaxel activity in non-small cell lung cancer cells.
    Owonikoko, Taofeek
    Ramalingam, Suresh
    Kanterewicz, Beatriz
    Balius, Trent
    Belani, Chandra
    Hershberger, Pamela
    CANCER RESEARCH, 2009, 69
  • [7] Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer
    Nobuyuki Yamamoto
    Yasumasa Nishimura
    Kazuhiko Nakagawa
    Kaoru Matsui
    Masahiro Fukuoka
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 285 - 291
  • [8] Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer
    Yamamoto, N
    Nishimura, Y
    Nakagawa, K
    Matsui, K
    Fukuoka, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (03) : 285 - 291
  • [9] Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer
    Watanabe, H
    Yamamoto, N
    Tamura, T
    Shimoyama, T
    Hotta, K
    Inoue, A
    Sawada, M
    Akiyama, Y
    Kusaba, H
    Nokihara, H
    Sekine, I
    Kunitoh, H
    Ohe, Y
    Kodama, T
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (12) : 626 - 630
  • [10] A dose escalation study of carboplatin plus vinorelbine for advanced non-small cell lung cancer
    Colleoni, M
    Nelli, I
    Gaion, F
    Pancheri, E
    Sgarbossa, G
    Manente, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1094 - 1094
12345